GNE, Polyclonal Antibody

NM; DMRV; IBM2; Uae1; GLCNE

For Research Use Only. Not for use in diagnostic procedures.

Polyclonal

IgG

Rabbit

Affinity purification

Store at -20 degree C. Avoid freeze / thaw cycles.

Small volumes of anti-GNE antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

The protein encoded by this gene is a bifunctional enzyme that initiates and regulates the biosynthesis of N-acetylneuraminic acid (NeuAc), a precursor of sialic acids. It is a rate-limiting enzyme in the sialic acid biosynthetic pathway. Sialic acid modification of cell surface molecules is crucial for their function in many biologic processes, including cell adhesion and signal transduction. Differential sialylation of cell surface molecules is also implicated in the tumorigenicity and metastatic behavior of malignant cells. Mutations in this gene are associated with sialuria, autosomal recessive inclusion body myopathy, and Nonaka myopathy. Alternative splicing of this gene results in transcript variants encoding different isoforms.

Polyclonal

Western Blot (WB), Immunohistochemistry (IHC)

WB: 1:500 - 1:2000, IHC: 1:50 - 1:100

Western blot analysis of extracts of various cell lines, using GNE antibody at 1:1000 dilution.
Secondary antibody: HRP Goat Anti-Rabbit IgG (H+L) (MBS128200) at 1:10000 dilution.
Lysates/proteins: 25ug per lane.
Blocking buffer: 3% nonfat dry milk in TBST.
Detection: ECL Basic Kit.
Exposure time: 30s.

Immunohistochemistry of paraffin-embedded mouse brain using GNE antibody at dilution of 1:100 (40x lens).

Immunohistochemistry of paraffin-embedded rat brain using GNE antibody at dilution of 1:100 (40x lens).

Immunohistochemistry of paraffin-embedded human colon using GNE antibody at dilution of 1:100 (40x lens).

Immunohistochemistry of paraffin-embedded human esophagus using GNE antibody at dilution of 1:100 (40x lens).

Immunohistochemistry of paraffin-embedded human stomach using GNE antibody at dilution of 1:100 (40x lens).

Calculated MW: 79kDa
Molecular Weight: 722 (753)

glucosamine (UDP-N-acetyl)-2-epimerase/N-acetylmannosamine kinase

bifunctional UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase

Bifunctional UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase

GLCNE  [Similar Products]

GLCNE_HUMAN

The protein encoded by this gene is a bifunctional enzyme that initiates and regulates the biosynthesis of N-acetylneuraminic acid (NeuAc), a precursor of sialic acids. It is a rate-limiting enzyme in the sialic acid biosynthetic pathway. Sialic acid modification of cell surface molecules is crucial for their function in many biologic processes, including cell adhesion and signal transduction. Differential sialylation of cell surface molecules is also implicated in the tumorigenicity and metastatic behavior of malignant cells. Mutations in this gene are associated with sialuria, autosomal recessive inclusion body myopathy, and Nonaka myopathy. Alternative splicing of this gene results in transcript variants encoding different isoforms. [provided by RefSeq, Jul 2008]

GNE: Regulates and initiates biosynthesis of N- acetylneuraminic acid (NeuAc), a precursor of sialic acids. Plays an essential role in early development. Required for normal sialylation in hematopoietic cells. Sialylation is implicated in cell adhesion, signal transduction, tumorigenicity and metastatic behavior of malignant cells. Defects in GNE are a cause of sialuria (SIALURIA); also known as sialuria French type. In sialuria, free sialic acid accumulates in the cytoplasm and gram quantities of neuraminic acid are secreted in the urine. The metabolic defect involves lack of feedback inhibition of UDP-GlcNAc 2-epimerase by CMP-Neu5Ac, resulting in constitutive overproduction of free Neu5Ac. Clinical features include variable degrees of developmental delay, coarse facial features and hepatomegaly. Sialuria inheritance is autosomal dominant. Defects in GNE are the cause of inclusion body myopathy type 2 (IBM2). Hereditary inclusion body myopathies are a group of neuromuscular disorders characterized by ***** onset, slowly progressive distal and proximal weakness and a typical muscle pathology including rimmed vacuoles and filamentous inclusions. IBM2 is an autosomal recessive disorder affecting mainly leg muscles, but with an unusual distribution that spares the quadriceps as also observed in Nonaka myopathy. Defects in GNE are the cause of Nonaka myopathy (NM); also known as distal myopathy with rimmed vacuoles (DMRV). NM is an autosomal recessive muscular disorder, allelic to inclusion body myopathy 2. It is characterized by weakness of the anterior compartment of the lower limbs with onset in early *****hood, and sparing of the quadriceps muscles. As the inclusion body myopathy, NM is histologically characterized by the presence of numerous rimmed vacuoles without inflammatory changes in muscle specimens. 5 isoforms of the human protein are produced by alternative splicing.

Protein type: Cell adhesion; EC 3.2.1.183; Isomerase; Kinase, other; EC 2.7.1.60; Cytoskeletal; Carbohydrate Metabolism - amino sugar and nucleotide sugar; Motility/polarity/chemotaxis

Chromosomal Location of Human Ortholog: 9p13.3

Cellular Component: cytoplasm; cytosol

Molecular Function: ATP binding; hydrolase activity, hydrolyzing O-glycosyl compounds; metal ion binding; N-acylmannosamine kinase activity; protein binding; UDP-N-acetylglucosamine 2-epimerase activity

Biological Process: carbohydrate phosphorylation; cell adhesion; cellular protein metabolic process; dolichol-linked oligosaccharide biosynthetic process; N-acetylglucosamine biosynthetic process; N-acetylneuraminate metabolic process; post-translational protein modification; protein amino acid N-linked glycosylation via asparagine; UDP-N-acetylglucosamine metabolic process

Disease: Inclusion Body Myopathy 2, Autosomal Recessive; Nonaka Myopathy; Sialuria

All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.

While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.